Abstract
Daptomycin recently made available in Chile, belongs to a new family of antimicrobials known as lypopeptides. Daptomycin has a unique mechanism of action and a potent bactericidal activity over susceptible agents. It is active against a number of clinically signifi cant Gram positive cocci, including strains of Staphylococcus aureus and Enterococcus spp., both susceptible and resistant to classic antimicrobials. Daptomycin has been approved for clinical use in skin and soft tissue infections, and for S. aureus bacteremia in adult patients. Ongoing trials suggest that daptomycin is also useful in the treatment of other infections such as osteomyelitis, biofi lm producing infections, and in immunocompromised patients, particularly onco-hematologic patients. The main adverse reaction associated with daptomycin use is myopathy, usually mild and reversible.
Author supplied keywords
Cite
CITATION STYLE
Araos, R., García, P., Chanqueo, L., & Labarca, J. (2012). Daptomicina: Características farmacológicas y aporte en el tratamiento de infecciones por cocáceas gram positivas. Revista Chilena de Infectologia, 29(2), 127–131. https://doi.org/10.4067/S0716-10182012000200001
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.